Century Therapeutics, Inc.
Develops iPSC-derived allogeneic cell therapies for cancer and autoimmune diseases.
IPSC | US
Overview
Corporate Details
- ISIN(s):
- US15673T1007
- LEI:
- Country:
- United States of America
- Address:
- 25 N 38TH STREET, 11TH FLOOR, 19104 PHILADELPHIA
- Website:
- https://www.centurytx.com/
- Sector:
- Manufacturing
Description
Century Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing allogeneic cell therapies derived from induced pluripotent stem cells (iPSCs). The company's platform utilizes the self-renewing capacity of iPSCs, combined with advanced cellular engineering and manufacturing, to create 'off-the-shelf' natural killer (NK) and T cell product candidates. These therapies are being developed for the treatment of hematological malignancies, solid tumors, and autoimmune diseases. Century aims to overcome the limitations of existing cell therapies by designing products with enhanced functionalities that are intended to be more effective, tolerable, and accessible for patients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Century Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Century Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Century Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
